Future breast cancer care: ESMO Breast Cancer 2024
Welcome to our coverage of ESMO Breast Cancer 2024, held in Berlin, Germany, on 15–17 May 2024. Read on for the latest advances in early breast cancer treatment, as well as innovative approaches for metastatic and triple-negative breast cancers.
ELEANOR, IMpassion132 and more
Including real-world diarrhoea rates and targeted combination for mBC
FeDeriCa and MORPHEUS-panBC
Data in HER2-positive EBC and metastatic triple-negative breast cancer
TROPION-Breast01, HER2DX decision support
A genomic crystal ball for HER2+ cancer treatment response?
Aromatase inhibitor face-off
Head-to-head AI trial and benefit from ovarian function suppression
This content has been developed independently by Medthority who previously received educational funding in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.